Alfa Genetics is a cross-sectional study, considered as a complementary visit to the Alfa Study, with the objective of expanding the cognitive, genetic and brain characterization of cognitively healthy people, in order to be able to detect early Alzheimer's disease.
The study will have about 1,700 participants. All of them will be given a magnetic resonance, in order to be able to identify brain morphological patterns associated with specific genetic variants that may be related to the risk of developing Alzheimer's disease.
On the other hand, it also includes an odor identification test, a blood extraction to carry out a genetic analysis and determine basic biochemical variables, and an update of the clinical history and the cognitive tests.
Within the framework of this study, there is a collaboration agreement with the National Center for Cardiovascular Surgery Carlos III (CNIC), to investigate the relationship between atherosclerotic disease and Alzheimer's disease. The agreement provides for the incorporation, in the future, of vascular image studies in the participants of the Alfa Genetics Study, and cognitive and neuroimaging studies in the PESA-CNIC-SANTANDER cohort.
Principal Investigator of Alfa Genetics
José Luis Molinuevo, scientific director of the Alzheimer's Prevention Program.
Molinuevo is co-author of more than 300 scientific articles with more than 15,000 citations in prestigious journals, and a 63 h index. In addition, he participates in networks related to the standardization of procedures and clinical criteria of Alzheimer’s disease, such as the Alzheimer Biomarker Standarization Initiative, the International Working Group, the National Institute on Aging and Alzheimer's Association (NIA-AA) Research framework, the CSF Appropriate Use Criteria Workgroup, the Standardization of CSF Preanalytics Working Group and the Subjective Cognitive Decline Initiative (SCD-I) Working Group.